These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8000111)

  • 41. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.
    Nygaard B; Metcalfe RA; Phipps J; Weetman AP; Hegedüs L
    J Endocrinol Invest; 1999 Jun; 22(6):481-5. PubMed ID: 10435860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study.
    Watanabe N; Noh JY; Kozaki A; Iwaku K; Sekiya K; Kosuga Y; Matsumoto M; Suzuki M; Yoshihara A; Ohye H; Kobayashi S; Kunii Y; Mukasa K; Sugino K; Inoue T; Ito K
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2700-8. PubMed ID: 25965082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endocrine ophthalmopathy and radioiodine therapy.
    Karlsson FA
    Acta Oncol; 2006; 45(8):1046-50. PubMed ID: 17118837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transient hypothyroidism after iodine-131 treatment of Graves' disease.
    Gómez JM; Virgili N; Soler J; Fernández M; Montaña E
    Thyroidology; 1989 Dec; 1(3):149-52. PubMed ID: 2484879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Graves' disease in HTLV-I carriers.
    Kawai H; Yokoi K; Akaike M; Kunishige M; Abe M; Tanouchi Y; Mine H; Mimura Y; Saito S
    J Mol Med (Berl); 1995 Feb; 73(2):85-8. PubMed ID: 7627634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
    Batra R; Krishnasamy SK; Buch H; Sandramouli S
    Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radioiodine associated de novo Graves' opthalmopathy in an Asian cohort.
    Tay WL; Tong AKT; Hui KYD; Tang YLC; Chng CL
    Hell J Nucl Med; 2017; 20(3):227-231. PubMed ID: 29177260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China.
    Tominaga T; Yokoyama N; Nagataki S; Cho BY; Koh CS; Chen JL; Shi Y
    Thyroid; 1997 Apr; 7(2):217-20. PubMed ID: 9133688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radioiodine therapy and Graves' ophthalmopathy.
    Bartalena L
    Nucl Med Commun; 2002 Nov; 23(11):1143-5. PubMed ID: 12411845
    [No Abstract]   [Full Text] [Related]  

  • 50. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy.
    Legler UF
    Horm Metab Res; 1987 Apr; 19(4):168-70. PubMed ID: 3583222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.
    Bartalena L; Marcocci C; Bogazzi F; Panicucci M; Lepri A; Pinchera A
    N Engl J Med; 1989 Nov; 321(20):1349-52. PubMed ID: 2811943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human T lymphotropic virus type 1 uveitis after Graves' disease.
    Yamaguchi K; Mochizuki M; Watanabe T; Yoshimura K; Shirao M; Araki S; Miyata N; Mori S; Kiyokawa T; Takatsuki K
    Br J Ophthalmol; 1994 Mar; 78(3):163-6. PubMed ID: 8148330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid remnant radioiodine ablation in a case of concurrent thyroid carcinoma, Graves' disease, and thyroid ophthalmopathy.
    Mansberg R
    Clin Nucl Med; 2007 Jul; 32(7):513-5. PubMed ID: 17581332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute pre-tibial myxoedema following radioiodine therapy for thyrotoxic Graves' disease.
    Harvey RD; Metcalfe RA; Morteo C; Furmaniak W; Weetman AP; Bevan JS
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):657-60; discussion 661. PubMed ID: 7634509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Myelopathy with uveitis in association with HTLV-I mimicking neuro-Behçet's disease].
    Saito Y; Ando T; Kameyama T; Takahashi A; Horiguchi M
    Rinsho Shinkeigaku; 1993 Aug; 33(8):912-4. PubMed ID: 8261708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum antibodies reactive with eye muscle antigens and the TSH receptor in a euthyroid subject who developed ophthalmopathy and Graves' hyperthyroidism.
    Wall J; Barsouk A; Stolarski C; Kiljanski J; Stachura I; Nebes V; Peele K; Volpe R; Kennerdell J
    Thyroid; 1996 Aug; 6(4):353-8. PubMed ID: 8875760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
    Mourits MP; Prummel MF; Wiersinga WM; Koornneef L
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):9-14. PubMed ID: 9302365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioiodine and Graves' ophthalmopathy reconsidered.
    Noury AM; Stanford MR; Graham EM
    Nucl Med Commun; 2001 Nov; 22(11):1167-9. PubMed ID: 11606880
    [No Abstract]   [Full Text] [Related]  

  • 60. Radioiodine treatment for graves' disease: a 10-year Australian cohort study.
    Fanning E; Inder WJ; Mackenzie E
    BMC Endocr Disord; 2018 Dec; 18(1):94. PubMed ID: 30541519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.